Barrie Ward (Executive Chairman) Board member
 Barrie Ward holds a BSc and PhD in microbial biochemistry from the University of Bath. From 1984-94 Barrie served as Director of the Microbiology Division of Glaxo Research and Development, with responsibility for infectious disease research. He was appointed Chairman and CEO of Virus Research Institute Inc., which in 1998 merged with T-Cell Sciences Inc. to form AVANT Immunotherapeutics Inc. In 1999 Barrie became Chief Executive Officer of KuDOS Pharmaceuticals Limited and served until January 2006 when the company was acquired by AstraZeneca. KuDOS was focused on the discovery and development of inhibitors of DNA repair as new treatments for cancer. Barrie is currently on the boards of Spirogen, Onyvax, Cancer Research Technology, Pharming Group N.V. and Biotica.
Tim Fell (Chief Operating Officer) Board member
 Following his D.Phil in Semiconductor Materials Tim migrated to the biological sciences in 1992 to work with DNA microarray pioneer Prof Ed Southern at Oxford University. In 1999 he co-founded Oxford Gene Technology (Operations) Ltd where as Technical Director, and later as General Manager, he developed a DNA microarray fee-for-service business. In 2002 UK anti-infective drug discovery company Arrow Therapeutics Ltd acquired the business and he joined the management team as CTO. His last role was with the London Technology Network, which he joined in 2005 as a Technology Consultant with a remit to stimulate collaboration between global business and the academic research base in the South East of England. Tim has an MBA from the London Business School. He joined CellCentric in March 2006.
Nessa Carey (Director of Exploratory Research)
 Nessa obtained a degree in Immunology from North East Surrey College of Technology and her PhD in Virology from the University of Edinburgh. Following a post-doctoral position in human neurogenetics at Charing Cross and Westminster Medical School she became a Lecturer and then Senior Lecturer in Molecular Biology at Imperial College School of Medicine. In 2001 Nessa joined Vernalis in the days when it was a specialist neuroscience company, initially as Director of Molecular Biology and ultimately as Head of Molecular Biology and Pharmacology. In 2004 she moved into oncology and epigenetics drug discovery, becoming Head of Biology for TopoTarget before joining CellCentric in June 2006.
Dev Crease (Patent Counsel – Part-time)
 Devanand Crease is a Chartered and European Patent Attorney and has worked in the life science field for over ten years. He has a PhD in Molecular and Developmental Biology from the University of Cambridge, where he worked in the laboratory of Sir John Gurdon - now part of the Gurdon Institute. Dev has represented established and emerging biotech and medical technology companies based in the UK, US and Asia, as well as private equity investors with interests in the UK and European biotechnology sector. As a result, Dev has gained valuable experience of a variety of IP and patent strategies adopted by a number of high profile bioscience companies. Since January 2004, Dev has headed the Bioscience Group at Keltie, and since September 2007 works part-time in-house at CellCentric.
Thea Stanway (Finance Officer)
Thea is a UK maths graduate and chartered accountant having trained with Peat Marwick (London and Bristol) and Coopers and Lybrand (Cambridge) back in the mid eighties. She has over 20 years post-qualification experience. Thea has very wide ranging experience particularly having worked with the needs of small growing high tech businesses both in practice and outside. She has worked within the life sciences business sector before gaining overseas experience working in Norway between 1995 and 1999, reporting under both US and UK GAAP. She joined CellCentric in Nov 2007.
|
|
Will West (Chief Executive) Board member
 Will completed his PhD in immunology and virology in 1992, sponsored by Unilever (UniPath). He held a post-doctoral position at the National Institute of Biological Standards and Control before joining Procter & Gamble Healthcare in 1994. He was responsible for clinical development in a number of therapeutic areas. He led an international team and delivered programmes throughout Europe, the Americas, South Africa and China. In 2001 he joined CellFactors plc, a tissue engineering biotechnology company in Cambridge, UK, where he was responsible for Product and Business Development. In 2004 he was recruited by Avlar BioVentures to help initiate CellCentric.
Will holds a Masters degree in Clinical Research as well as an MBA from London Business School. He sits on an advisory committee of the BioIndustry Association and is on the Research Steering Group of a Wellcome Trust-backed tissue engineering company. He is currently involved in the UK government’s review of bioscience through the New Ideas Working Group of the BIGT initiative. Will was appointed CEO in November 2005.
David Knowles (President & Chief Scientific Officer)
 David Knowles was awarded a PhD from the Department of Biochemistry, Imperial College of Science and Technology, London in 1977. He joined May & Baker, a division of Rhone Poulenc, to work on therapeutic approaches targeting bacterial adhesion. Since then, he established an international reputation in anti-infectives research and development and has worked in several major international pharmaceutical companies including Beecham Pharmaceuticals, Wellcome Research Laboratories and SmithKline Beecham. In 1995 he was appointed Director of Molecular Microbiology at SmithKline Beecham, based in Pennsylvania. He returned to the UK at the end of 1996 and gained useful experience in anti-infective development at SB before embarking on a career in the biotech sector.
In 1999, he joined the board of RiboTargets plc and served as CSO for over 3 years before becoming Director of R&D at British Biotech, where he oversaw the merger with Vernalis. David worked as an independent consultant for a number of Private Equity Investors from the UK, Europe and the USA before becoming CSO and R&D Director for Piramed Ltd. in 2005. He has served on the Scientific Advisory and Supervisory Boards of a number of biotech companies, including MerLion Pharmaceuticals and Axxima AG. He is a non-executive director of Procarta Biosystems. He is a past Member of Council of the American Society for Microbiology and is on the editorial board of Current Opinions in Microbiology.
Neil Pegg (Director of Discovery Research)
 Neil was awarded a PhD in organic chemistry from the University of Nottingham in 1987, having completed undergraduate study at the University of Bristol. Following postdoctoral research at Ohio State University, Neil joined Glaxo in 1989, where he led successful teams working on both Lead Generation and Lead Optimization programmes. In 2001 Neil joined OSI Pharmaceuticals firstly as Associate Director of Oncology Chemistry and from 2003 as Director of UK Discovery Chemistry. In 2005 Neil was appointed Research Director of ReOx Ltd, a start-up drug discovery company exploiting pioneering work in the field of hypoxia, before joining Piramed Ltd in 2006 as Director of Chemistry. Piramed was acquired by Roche in 2008. Neil has worked in several therapeutic areas, including Oncology, Immune/Inflammation, Pain, CNS and Cardiovascular Disease with direct involvement in multiple compounds progressing into Development.
Richard Brooks (Finance Director - Part-time)
 Richard qualified as a chartered accountant in 1984 having trained with Ernst and Young (Edinburgh and London). After 8 years in industry Richard founded FD Solutions in 1993. It is now the market leader in the UK for the provision of part time Finance Director services and Richard manages around 50 staff providing finance director services to over 100 businesses. Richard is a seasoned professional with over 20 years of experience managing the finances of growing entrepreneurial businesses. Richard has a particular interest in technology businesses and systems development and implementation. Richard joined Cellcentric as part time Finance Director in July 2006.
|
